246 related articles for article (PubMed ID: 32578444)
21. Transcript and in silico analysis of CLN3 in juvenile neuronal ceroid lipofuscinosis and associated mouse models.
Chan CH; Mitchison HM; Pearce DA
Hum Mol Genet; 2008 Nov; 17(21):3332-9. PubMed ID: 18678598
[TBL] [Abstract][Full Text] [Related]
22. CLN3 protein is targeted to neuronal synapses but excluded from synaptic vesicles: new clues to Batten disease.
Luiro K; Kopra O; Lehtovirta M; Jalanko A
Hum Mol Genet; 2001 Sep; 10(19):2123-31. PubMed ID: 11590129
[TBL] [Abstract][Full Text] [Related]
23. Developmental impairments of select neurotransmitter systems in brains of Cln3(Deltaex7/8) knock-in mice, an animal model of juvenile neuronal ceroid lipofuscinosis.
Herrmann P; Druckrey-Fiskaaen C; Kouznetsova E; Heinitz K; Bigl M; Cotman SL; Schliebs R
J Neurosci Res; 2008 Jun; 86(8):1857-70. PubMed ID: 18265413
[TBL] [Abstract][Full Text] [Related]
24. Gene Therapy Approaches to Treat the Neurodegeneration and Visual Failure in Neuronal Ceroid Lipofuscinoses.
Kleine Holthaus SM; Smith AJ; Mole SE; Ali RR
Adv Exp Med Biol; 2018; 1074():91-99. PubMed ID: 29721932
[TBL] [Abstract][Full Text] [Related]
25. Modulating membrane fluidity corrects Batten disease phenotypes in vitro and in vivo.
Schultz ML; Tecedor L; Lysenko E; Ramachandran S; Stein CS; Davidson BL
Neurobiol Dis; 2018 Jul; 115():182-193. PubMed ID: 29660499
[TBL] [Abstract][Full Text] [Related]
26. Caspase 1 activity influences juvenile Batten disease (CLN3) pathogenesis.
Burkovetskaya M; Bosch ME; Karpuk N; Fallet R; Kielian T
J Neurochem; 2019 Mar; 148(5):652-668. PubMed ID: 29873075
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic efficacy of antisense oligonucleotides in mouse models of CLN3 Batten disease.
Centa JL; Jodelka FM; Hinrich AJ; Johnson TB; Ochaba J; Jackson M; Duelli DM; Weimer JM; Rigo F; Hastings ML
Nat Med; 2020 Sep; 26(9):1444-1451. PubMed ID: 32719489
[TBL] [Abstract][Full Text] [Related]
28. A tailored Cln3
Langin L; Johnson TB; Kovács AD; Pearce DA; Weimer JM
Sci Rep; 2020 Jun; 10(1):10591. PubMed ID: 32601357
[TBL] [Abstract][Full Text] [Related]
29. A knock-in reporter mouse model for Batten disease reveals predominant expression of Cln3 in visual, limbic and subcortical motor structures.
Ding SL; Tecedor L; Stein CS; Davidson BL
Neurobiol Dis; 2011 Feb; 41(2):237-48. PubMed ID: 20875858
[TBL] [Abstract][Full Text] [Related]
30. Retinal Phenotype of Patients With Isolated Retinal Degeneration Due to CLN3 Pathogenic Variants in a French Retinitis Pigmentosa Cohort.
Smirnov VM; Nassisi M; Solis Hernandez C; Méjécase C; El Shamieh S; Condroyer C; Antonio A; Meunier I; Andrieu C; Defoort-Dhellemmes S; Mohand-Said S; Sahel JA; Audo I; Zeitz C
JAMA Ophthalmol; 2021 Mar; 139(3):278-291. PubMed ID: 33507216
[TBL] [Abstract][Full Text] [Related]
31. Phenotypic characterization of a mouse model of juvenile neuronal ceroid lipofuscinosis.
Katz ML; Johnson GS; Tullis GE; Lei B
Neurobiol Dis; 2008 Feb; 29(2):242-53. PubMed ID: 17962032
[TBL] [Abstract][Full Text] [Related]
32. Altered gene expression in the eye of a mouse model for batten disease.
Chattopadhyay S; Kingsley E; Serour A; Curran TM; Brooks AI; Pearce DA
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):2893-905. PubMed ID: 15326100
[TBL] [Abstract][Full Text] [Related]
33. A human model of Batten disease shows role of CLN3 in phagocytosis at the photoreceptor-RPE interface.
Tang C; Han J; Dalvi S; Manian K; Winschel L; Volland S; Soto CA; Galloway CA; Spencer W; Roll M; Milliner C; Bonilha VL; Johnson TB; Latchney L; Weimer JM; Augustine EF; Mink JW; Gullapalli VK; Chung M; Williams DS; Singh R
Commun Biol; 2021 Feb; 4(1):161. PubMed ID: 33547385
[TBL] [Abstract][Full Text] [Related]
34. Age-dependent alterations in neuronal activity in the hippocampus and visual cortex in a mouse model of Juvenile Neuronal Ceroid Lipofuscinosis (CLN3).
Burkovetskaya M; Karpuk N; Kielian T
Neurobiol Dis; 2017 Apr; 100():19-29. PubMed ID: 28042098
[TBL] [Abstract][Full Text] [Related]
35. Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten disease.
Kovács AD; Saje A; Wong A; Ramji S; Cooper JD; Pearce DA
Neuropharmacology; 2012 Oct; 63(5):769-75. PubMed ID: 22683643
[TBL] [Abstract][Full Text] [Related]
36. Altered arginine metabolism in the central nervous system (CNS) of the Cln3-/- mouse model of juvenile Batten disease.
Chan CH; Ramirez-Montealegre D; Pearce DA
Neuropathol Appl Neurobiol; 2009 Apr; 35(2):189-207. PubMed ID: 19284480
[TBL] [Abstract][Full Text] [Related]
37. Histopathologic and immunocytochemical analysis of the retina and ocular tissues in Batten disease.
Bensaoula T; Shibuya H; Katz ML; Smith JE; Johnson GS; John SK; Milam AH
Ophthalmology; 2000 Sep; 107(9):1746-53. PubMed ID: 10964839
[TBL] [Abstract][Full Text] [Related]
38. A novel porcine model of CLN3 Batten disease recapitulates clinical phenotypes.
Swier VJ; White KA; Johnson TB; Wang X; Han J; Pearce DA; Singh R; Drack AV; Pfeifer W; Rogers CS; Brudvig JJ; Weimer JM
Dis Model Mech; 2023 Aug; 16(8):. PubMed ID: 37305926
[TBL] [Abstract][Full Text] [Related]
39. Ocular morphology and function in juvenile neuronal ceroid lipofuscinosis (CLN3) in the first decade of life.
Preising MN; Abura M; Jäger M; Wassill KH; Lorenz B
Ophthalmic Genet; 2017; 38(3):252-259. PubMed ID: 27486012
[TBL] [Abstract][Full Text] [Related]
40. Searching for novel biomarkers using a mouse model of CLN3-Batten disease.
Timm D; Cain JT; Geraets RD; White KA; Koh SY; Kielian T; Pearce DA; Hastings ML; Weimer JM
PLoS One; 2018; 13(8):e0201470. PubMed ID: 30086172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
